OncoSec Medical (NSDQ:ONCS) said today that it inked a research deal with Dr. Roger Lo and his research team at the University of California Los Angeles to study participants from the biotech company’s Pisces/Keynote-695 Phase IIb clinical trial.
Dr. Lo and his team are slated to perform genetic, transcriptomic and methylomic analyses of patients from OncoSec’s melanoma trial, which is focused on the intra-tumoral delivery of tavokinogene telseplasmid combined with Merck‘s (NYSE:MRK) Keytruda for people with metastatic melanoma.
Get the full story at our sister site, Drug Delivery Business News.
The post OncoSec inks research deal to analyze clinical trial participants appeared first on MassDevice.
from MassDevice https://ift.tt/2M7nRxG
Cap comentari:
Publica un comentari a l'entrada